This reporting period companies based in California operating in the biotechnology industry and that have raised late stage financing led the pack in the amount of venture financing raised. There were no initial public offerings this week.
You can still submit your business plan to CapitalHunter.com, for a free review by our experienced staff of analysts and see if you qualify for investment capital. Also, if you want to advertise with our newsletter (circulation 20,000) call us at 619-236-9998 and we can make an arrangement suitable for you.
|
 |
CapitalHunter.com was able to verify that $431 million of venture capital was invested in 27 U.S.-based companies during this week’s reporting period. The average deal size was approximately 15.96 million. The amount of venture capital invested this period increased by 11% compared to last periods $389 million. |
|
|
 |
Geographically, twenty California companies raised $168 million in new equity financing, which represents 40% of the total venture capital invested this reporting period. The largest private venture financing in California this period was into Visto Corporation. Visto Corporation raised $66.6 million and is a Redwood, California based software company providing wireless messaging solutions to mobile operators for personal and corporate use. |
|
|
 |
The biotechnology sector raised 31% of the venture capital this period. Five biotechnology companies raised $133.9 million in venture financing. The largest private venture financing in the biotechnology sector this period was into Replidyne. Replidyne is a Louisville, Colorado based biopharmaceutical company currently developing next-generation antibacterial products. |
|
|
 |
Companies raising later stage financing rounds led this week’s venture capital activity. These financings represented 53% of the total venture capital deployed this period. The largest late stage private venture financing was placed into the aforementioned Redwood software company Visto. |
|
|
 |
|
The three largest venture deals this period are as follows: |
| |
Company |
Industry |
Investment |
| 1 |
Visto Corporation |
Software |
$66.6 million |
| 2 |
Replidyne |
Biotechnology |
$62.5 million |
| 3 |
Creditex |
Financial Services |
$57.3 million |
|
 |
|
The following sixteen and other unnamed investors funded the above mentioned top three venture capital investments for $186.44 million: |
| 1 | 3i Group | | 2 | Draper Fisher Jurvertson | | 3 | Duquesne Capital Management | | 4 | Healthcare Investment Partners | | 5 | HealthCare Ventures | | 6 | MDS Capital | | 7 | Meritech Capital Partners | | 8 | Morgenthaler Ventures | | 9 | Oak Investment Partners | | 10 | Perseus-Soros BioPharmaceutical Fund | | 11 | Quintiles Transnational | | 12 | Rustic Canyon Ventures | | 13 | Sequel Venture Partners | | 14 | TA Associates | | 15 | Temasek Holdings | | 16 | TPG Ventures |
|
A total of 57 equity financings of private and public companies occurred during this reporting period. Each of the 57 equity financings are profiled in a weekly report which include venture financings, private placements, secondary offerings, PIPE’s, and IPO’s.
About CapitalHunter.com
CapitalHunter.com is a web-based financial information company that identifies, preserves and electronically disseminates worldwide data on venture capital and other equity financings. Customers utilize the CapitalHunter.com searchable database to research newly and historic financings and to identify active investors.
Please visit www.capitalhunter.com and get immediate access. New subscribers can request a free investor analysis. |
|
|
|
©2003 Capital Hunter, Inc. all rights reserved
|
To be REMOVED from this free service, CLICK HERE |
